Search

Displaying results 991 - 1000 of 4233 in total
  1. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    [L38929] Multiple factors contribute to the development of congenital athymia, such as genetic abnormalities, congenital syndromes, and environmental factors. … Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital

  2. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.

  3. Drug

    Cyclobenzaprine

    go.drugbank.com/drugs/DB00924
    ApprovedInvestigational

    [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond. … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.

  4. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … [L15302] Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes,[L15292] as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic

  5. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.

  6. Drug

    Remifentanil

    go.drugbank.com/drugs/DB00899
    ApprovedInvestigational

    Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.

  7. Drug

    Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10990
    Approved

    Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received

  8. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Mast-cell stabilizers, first one approved being cromolyn sodium, are used in treatment of ocular hypersensitivity reactions such as vernal conjunctivitis. … These conditions often require treatment with anti-inflammatory medications such as ophthalmic NSAIDs or topical steroids which may cause systemic or toxic effects long-term.

  9. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    Grazoprevir is available as a fixed dose combination product with [DB11574] (tradename Zepatier) used for the treatment of chronic Hepatitis C. … Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Grazoprevir.

  10. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer